(Q37809121)

23 August 2017

Prediction and prevention of Type 1 diabetes mellitus (English)

1 reference

23 August 2017

0 references

2

George S Eisenbarth

1 reference

23 August 2017

Li Zhang

1

1 reference

PubMed ID

21073664

23 August 2017

language of work or name

1 reference

1 March 2011

1 reference

23 August 2017

1 reference

23 August 2017

3

1 reference

23 August 2017

1

1 reference

23 August 2017

48-57

1 reference

Entities and frequency of neonatal diabetes: data from the diabetes documentation and quality management system (DPV).

23 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Increasing incidence of type 1 diabetes in 0- to 17-year-old Colorado youth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Diabetes incidence in 0- to 14-year age-group in Italy: a 10-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

The incidence of type 1 diabetes is increasing in both children and young adults in Northern Italy: 1984-2004 temporal trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Type 1 diabetes: new perspectives on disease pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Gene dosage and suceptibility to insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Commonality in the genetic control of Type 1 diabetes in humans and NOD mice: variants of genes in the IL-2 pathway are associated with autoimmune diabetes in both species

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Susceptibility to type I diabetes: HLA-DQ and DR revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Genetics of type 1A diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

A genome-wide scan for type 1 diabetes susceptibility genes in nuclear families with multiple affected siblings in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Autoimmune type 1 diabetes genetic susceptibility encoded by human leukocyte antigen DRB1 and DQB1 genes in Tunisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Relative and absolute HLA-DQA1-DQB1 linked risk for developing type I diabetes before 40 years of age in the Belgian population: implications for future prevention studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Two single nucleotide polymorphisms identify the highest-risk diabetes HLA genotype: potential for rapid screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

A new automated human leukocyte antigen genotyping strategy to identify DR-DQ risk alleles for celiac disease and type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Autoantibodies to IA-2beta improve diabetes risk assessment in high-risk relatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington State Diabetes Prediction Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as in unaffected relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Humoral autoimmunity against the extracellular domain of the neuroendocrine autoantigen IA-2 heightens the risk of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

IA-2 antibody epitopes and isotypes during the prediabetic process in siblings of children with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Characterization of the humoral immune response to islet antigen 2 in children with newly diagnosed type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Antibodies to a 64,000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Optimized autoantibody-based risk assessment in family members. Implications for future intervention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Insulin autoantibodies as markers for type I diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease:

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Clinical applications of diabetes antibody testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Enhanced levels of cow's milk antibodies in infancy in children who develop type 1 diabetes later in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Effects of insulin in relatives of patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

GAD treatment and insulin secretion in recent-onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Rapid assays for detection of anti-islet autoantibodies: implications for organ donor screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Immunotherapy of type 1 diabetes--how to rationally prioritize combination therapies in T1D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

Genetics of type 1 diabetes in Asian and Caucasian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2010.00102.X

10.1111/J.1753-0407.2010.00102.X

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21073664